The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 17, 2018

Filed:

Nov. 27, 2013
Applicant:

Conopco, Inc., Englewood Cliffs, NJ (US);

Inventors:

Mark John Berry, Bedfordshire, GB;

Mark Ian Fowler, Bedfordshire, GB;

Alan David Heath, Bangalore, IN;

Assignee:

CONOPCO, INC., Englewood Cliffs, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A23L 1/30 (2006.01); A23L 2/52 (2006.01); A61K 31/05 (2006.01); A61K 31/7048 (2006.01); A61K 31/7034 (2006.01); A23L 33/10 (2016.01); A23L 33/105 (2016.01);
U.S. Cl.
CPC ...
A61K 31/7048 (2013.01); A23L 2/52 (2013.01); A23L 33/10 (2016.08); A23L 33/105 (2016.08); A61K 31/05 (2013.01); A61K 31/7034 (2013.01); A23V 2002/00 (2013.01); A23V 2200/00 (2013.01);
Abstract

Foods or meals high in available carbohydrate such as sucrose or starch increase postprandial blood glucose concentrations. Repeated high post-prandial plasma glucose 'spikes' are associated with an increased risk of developing type II diabetes. Unregulated glycemic excursions are undesirable, and any reduction or 'blunting' of the post-prandial glucose concentration in blood is potentially beneficial. This invention relates to an edible composition for delay of intestinal glucose uptake through synergistic inhibition of both active sodium glucose co-transporter 1 (SGLT1) and passive glucose transporter 2 (GLUT2) leading to flattening or blunting of the post-prandial glucose peak. In a first aspect of the invention, an edible composition is provided, in the form of a single serving of one or more unit dosages, wherein the edible composition comprises 20-2000, preferably 30-1000, most preferably 40-500 mg a 3,5-dihydroxy-trans-stilbene and 10-2000, preferably 20-1000, most preferably 40-500 mg flavonoid mono-glucoside or dihydrochalcone monoglucoside.


Find Patent Forward Citations

Loading…